Celldex Therapeutics (CLDX) | Stock Overview & Key Data
Celldex Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $3,375.00 on March 6, 2000
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Celldex Therapeutics CLDX | 1.74B Small-cap | 6.54% | 13.33% | 22.62% | 67.82% | 6.79% | -12.07% | -12.40% | 74.75% |
| Vertex VRTX | 107.98B Large-cap | 1.47% | 4.64% | -13.38% | -13.98% | 2.24% | -13.88% | 41.49% | 90.23% |
| Alnylam ALNY | 60.24B Large-cap | -0.88% | -5.22% | 42.41% | 87.84% | 95.60% | 60.72% | 146.29% | 214.27% |
| Vera Therapeutics VERA | 1.96B Small-cap | 4.59% | 21.73% | 26.10% | 38.65% | -27.65% | -28.53% | 59.18% | 165.48% |
| Viridian VRDN | 1.74B Small-cap | 2.78% | 7.92% | 27.99% | 84.99% | 10.37% | -7.70% | 4.01% | 164.36% |
| AbCellera Biologics ABCL | 1.72B Small-cap | -1.17% | 39.39% | 40.05% | 172.35% | 95.05% | 128.19% | -42.84% | -89.97% |
Ownership & Short Interest
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CLDX's 52-week high and low?
- In the last 52 weeks, Celldex Therapeutics reached a high of $31.66 (on October 14, 2024) and a low of $14.40 (on April 9, 2025).
- What is the market cap and P/E ratio for CLDX?
- Curious about Celldex Therapeutics's size and valuation? Its market capitalization stands at 1.74B. When it comes to valuation, the P/E ratio (trailing twelve months) is -11.03, and the forward P/E (looking ahead) is -8.12.
- Does CLDX pay dividends? If so, what's the yield?
- As for dividends, Celldex Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Celldex Therapeutics's main competitors or similar companies to consider before investing?
When looking at Celldex Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX107.98B Healthcare Biotechnology -13.88% 41.49% Alnylam
ALNY60.24B Healthcare Biotechnology 60.72% 146.29% Vera Therapeutics
VERA1.96B Healthcare Biotechnology -28.53% 59.18% Viridian
VRDN1.74B Healthcare Biotechnology -7.70% 4.01% AbCellera Biologics
ABCL1.72B Healthcare Biotechnology 128.19% -42.84% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Celldex Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Celldex Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -27.18%, the Debt to Equity ratio from the most recent quarter is 0.46, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for CLDX?
- Looking at Celldex Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $6M. Compared to the same quarter last year (YoY), quarterly revenue grew by -70.80%, and quarterly earnings saw a YoY growth of -70.78%.
- How much of CLDX stock is held by insiders and institutions?
- Wondering who owns Celldex Therapeutics stock? Company insiders (like executives and directors) hold about 0.19% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 111.24%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.